OPALE, the Organization
for Partnerships in Leukemia
The OPALE Carnot institute is a healthcare industry’s preferred partner for the research and development of innovative solutions aimed at diagnosis, treatment and follow-up of patients in the field of leukemia and related diseases, the deadliest blood cancer and first child cancer.
Unique leukemia R&D partnering opportunities
The OPALE Carnot Institute gives healthcare companies unique access to the expertise of an internationally unparalleled consortium in the field of leukemia and related diseases. Our aim is to prolong or save the lives of more patients by accelerating therapeutic and diagnostic innovation across the entire research and development value chain.
Explore our offer
Carnot, a label of excellence
Granted by the French Ministry of Higher Education, Research and Innovation, the Carnot label is prestigious and highly selective.
Being labelled Carnot is a guarantee of scientific and operational excellence in R&D collaborations for our industrial partners.
The Carnot institutes follow their namesake Charter to guarantee top-tier collaborative research, effectively driving industrial advancements while ensuring ongoing scientific revitalization within the Carnot community.
"The OPALE Carnot Institute addresses many of the needs of manufacturers in the leukemia market, thanks to the specialization and depth of its R&D offering, accessible through a one-stop shop."
Medical Director of a pharmaceutical company
Member of OPALE's Strategic Advisory Committee
"Accelerating the emergence of innovative solutions for the diagnosis, treatment, and follow-up of patients in the field of leukemia and related diseases"
Pr Hervé Dombret
OPALE's Chairman
News
Un organoïde 3D pour reproduire la moelle osseuse et accélérer la recherche contre la leucémie
11/08/2025
Un organoïde 3D reproduisant la moelle osseuse ouvre de nouvelles perspectives pour comprendre et traiter la leucémie.
> Read moreRésistance aux traitements dans les MDS/AML : une découverte clé ouvre de nouvelles perspectives thérapeutiques
09/08/2025
Une équipe de l’Institut Carnot OPALE révèle un mécanisme de résistance clé dans les MDS/AML avec mutation TP53 et ouvre la voie à une nouvelle stratégie thérapeutique combinée.
> Read moreLEUKEMIA 360 – Le rendez-vous international pour accélérer l’innovation contre la leucémie
18/07/2025
Le 13 novembre 2025, Paris accueillera la 2? édition de LEUKEMIA 360, un événement unique en Europe réunissant les acteurs majeurs de la recherche et de l’innovation contre la leucémie et les maladies apparentées.
> Read more